<DOC>
	<DOCNO>NCT01146678</DOCNO>
	<brief_summary>Primary Objective : - ass relative bioavailability single dose insulin glargine ( Lantus ) lixisenatide give subcutaneously on-site mix versus separate simultaneous injection drug Secondary Objectives : - compare activity single dose insulin glargine lixisenatide give subcutaneously on-site mix versus separate simultaneous injection drug - ass safety tolerability insulin glargine lixisenatide give subcutaneously on-site mix</brief_summary>
	<brief_title>Relative Bioavailability Activity Different Formulations Insulin Glargine Lixisenatide Patients With Diabetes Mellitus Type 1</brief_title>
	<detailed_description>The study period one patient one month average last 7 month ( + 2 week ) post-study follow-up visit</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Subjects type 1 diabetes mellitus one year total insulin dose &lt; 1.2 U.kg/day , otherwise healthy glycohemoglobin ( HbA1c ) â‰¤ 9.0 % , stable insulin regimen least 2 month prior study , normal find medical history physical examination . Exclusion criterion : history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart diabetes mellitus type I ) , hematological , neurological , psychiatric , systemic ( affect body whole ) , ocular , gynecologic ( female ) , infectious disease ; acute infectious disease sign acute illness More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month Frequent severe headache and/or migraine , recurrent nausea and/or vomit ( twice month ) Symptomatic hypotension , asymptomatic postural hypotension define decrease systolic blood pressure ( SBP ) equal great 20 mmHg within three minute change supine stand position Presence history drug allergy clinically significant allergic disease Likelihood require treatment study period drug permit clinical study protocol Pregnant breast feed woman Any medication within 14 day inclusion , within 5 time elimination halflife drug , whichever long regular use medication insulin last month study start exception thyroid hormone , lipidlowering antihypertensive drug , , female , exception hormonal contraception menopausal hormone replacement therapy , vaccination within last 28 day . Positive reaction follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis B core antibody ( antiHBc Ab ) compound possible immune activity , antihepatitis C virus ( antiHCV2 ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) History unexplained pancreatitis , chronic pancreatitis and/or pancreatectomy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>